Yu CD, Zhang K. Efficacy and safety of laparoscopic vs open gastrectomy after neoadjuvant therapy for locally advanced gastric cancer. World J Clin Cases 2023; 11(32): 7795-7805 [PMID: 38073690 DOI: 10.12998/wjcc.v11.i32.7795]
Corresponding Author of This Article
Chang-Da Yu, MSc, Associate Chief Physician, Department of General Surgery, Jiujiang First People’s Hospital, No. 48 Taling South Road, Jiujiang 332000, Jiangxi Province, China. ycd136359835661123@163.com
Research Domain of This Article
Medicine, General & Internal
Article-Type of This Article
Prospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Nov 16, 2023; 11(32): 7795-7805 Published online Nov 16, 2023. doi: 10.12998/wjcc.v11.i32.7795
Efficacy and safety of laparoscopic vs open gastrectomy after neoadjuvant therapy for locally advanced gastric cancer
Chang-Da Yu, Ke Zhang
Chang-Da Yu, Ke Zhang, Department of General Surgery, Jiujiang First People’s Hospital, Jiujiang 332000, Jiangxi Province, China
Author contributions: Yu CD and Zhang K contributed to the data collection; Yu CD and Zhang K contributed to the data collection; Yu CD and Zhang K contributed to the formal analysis; Yu CD and Zhang K participated in the survey; Yu CD and Zhang K contributed to these methods; Yu CD guided the research; Yu CD and Zhang K jointly validated this study; Zhang K contributed to the visualization of this study; Yu CD drafted the first draft; and Yu CD and Zhang K jointly reviewed and edited the manuscript.
Institutional review board statement: This study was reviewed and approved by the Medical Ethics Committee of Jiujiang First People’s Hospital.
Clinical trial registration statement: This study was registered at the Clinical Trial Registration Center Testing Center. The registration identification number is (researchregistry9243).
Informed consent statement: All study participants or their legal guardians provided written informed consent before study enrollment.
Conflict-of-interest statement: We have no financial relationships to disclose.
Data sharing statement: There is no additional data available.
CONSORT 2010 statement: The authors have read the CONSORT 2010 statement, and the manuscript was prepared and revised according to the CONSORT 2010 statement.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Chang-Da Yu, MSc, Associate Chief Physician, Department of General Surgery, Jiujiang First People’s Hospital, No. 48 Taling South Road, Jiujiang 332000, Jiangxi Province, China. ycd136359835661123@163.com
Received: September 21, 2023 Peer-review started: September 21, 2023 First decision: October 9, 2023 Revised: October 10, 2023 Accepted: October 30, 2023 Article in press: October 30, 2023 Published online: November 16, 2023 Processing time: 55 Days and 18.4 Hours
Core Tip
Core Tip: Laparoscopic gastrectomy (LG) is a viable and safe approach to treating locally advanced gastric cancer (LAGC) following neoadjuvant therapy (NAT). This study aimed to compare the efficacy and safety of LG vs open gastrectomy (OG) after NAT in patients with LAGC. The results demonstrated comparable overall survival and disease-free survival rates between the two groups. Additionally, LG exhibits advantages such as reduced blood loss, a shorter hospital stay, and a lower incidence of surgical site infection than OG. The two groups had similar rates of other surgical complications. Furthermore, LG yielded better quality of life (QOL) scores in terms of physical functioning, role functioning, global health status, fatigue, pain, appetite loss, and body image at 6 months postoperatively. These findings suggest that LG after NAT is a feasible and safe option for LAGC, providing comparable survival outcomes along with improved short-term recovery and QOL compared to OG.
